APPLY: A prospective observational study of clinical practice patterns of darbepoetin alfa use in patients with chemotherapy-induced anemia in Romania

被引：2

作者：

Berbec N.M. ^{[1
]}

Stanculeanu D.L. ^{[2
]}

Badelita N.S. ^{[3
]}

Vasilica M. ^{[3
]}

Popovici D.I. ^{[4
]}

Colita A. ^{[1
]}

Neacsu C. ^{[5
]}

Iordan A. ^{[5
]}

机构：

[1] Colţea Clinical Hospital, 1 Ion C. Brătianu Bd, Bucharest

[2] Institute of Oncology “Prof. Dr. Al Trestioreanu”, 252 Fundeni Rd, 2nd District, Bucharest

[3] Fundeni Clinical Institute, 258 Fundeni Rd., Bucharest

[4] OncoHelp Clinic, 59 Ciprian Porumbescu St., Timisoara

[5] Amgen Romania, 1A Bucuresti-Ploiesti Rd., 1st District, Bucharest

来源：

memo - Magazine of European Medical Oncology | 2018年 / 11卷 / 2期

关键词：

Chemotherapy-induced anemia; Darbepoetin alfa; EORTC guidelines; Fatigue; Hemoglobin; Romanian National Therapeutic Protocol on ESA prescription;

D O I：

10.1007/s12254-018-0390-4

中图分类号：

学科分类号：

摘要：

Purpose: The primary objective of this study was to evaluate the compliance of Romanian physicians with the national therapeutic protocol and international guidelines on treatment with erythropoiesis-stimulating agents in anemic cancer patients receiving chemotherapy. The secondary objective was to assess the hemoglobin (Hb) level change due to anemia treatment and safety of darbepoetin alfa. Methods: This was a single-arm, prospective, longitudinal, multicenter, observational study in patients with nonmyeloid malignancies and symptomatic chemotherapy-induced anemia treated concomitantly with darbepoetin alfa. Patients were followed for the duration of chemotherapy, but no shorter than three and no longer than eight cycles, irrespective of their exposure to darbepoetin alfa. Results: In this study, 497 patients with a mean age of 60.6 years were analyzed. Most patients (80.7%) were initiated on darbepoetin alfa at a Hb of 9–11 g/dL, congruent with recommendations. The median Hb increased by 0.9 g/dL between baseline and week 12. Hb target achievement was higher among patients treated according to guidelines than those initiated at Hb < 9 g/dL. A similar trend was observed for red blood cell transfusion requirements. No new safety signals were reported for darbepoetin alfa. Conclusions: The majority of patients were treated according to national and international recommendations. Guideline adherence was associated with more frequent achievement of Hb targets and lower red blood cell transfusion requirements compared with patients starting anemia treatment with darbepoetin alfa at lower-than-recommended Hb levels. © 2018, The Author(s).

引用

页码：144 / 151

页数：7

共 13 条

[1]

Groopman J.E., Itri L.M., Chemotherapy-induced anemia in adults: incidence and treatment, J Natl Cancer Inst, 91, 19, pp. 1616-1634, (1999)

[2]

Ludwig H., Fritz E., Anemia in cancer patients, Semin Oncol, 25, pp. 2-6, (1998)

[3]

Cella D., Lai J.S., Chang C.H., Peterman A., Slavin M., Fatigue in cancer patients compared with fatigue in the general United States population, Cancer, 94, 2, pp. 528-538, (2002)

[4]

Aapro M.S., Link H., September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents, Oncologist, 13, pp. 33-36, (2008)

[5]

Schrijvers D., De Samblanx H., Roila F., Group EGW E.G.W., Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO clinical practice guidelines for use, Ann Oncol, 21, pp. v244-v247, (2010)

[6]

Aranesp summary of product characteristics. European Medicines Agency, (2015)

[7]

Romanian-protocol 2008, Health Minister Order 1301/500 from 11 july 2008, (2008)

[8]

Pettengell R., Silvestre A.S., Schwenkglenks M., Rossi F.G., Duehrsen U., Verhoef G., Lugtenburg P.J., Wheeler T., Pujol B., Haioun C., Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R) CHOP, Hematology, 18, 1, pp. 26-29, (2013)

[9]

Boguradzki P., Boer K., Cipkova A., Wojciechowska-Lampka E., Schutzova M., Ocvirk J., Toth E., Oncology Pro. a Prospective Data Audit of the Management of Chemotherapy-Induced Anemia with Darbepoetin Alfa 6 the APRIORI Study, (2012)

[10]

Van Belle S., Karanikiotis C., Labourey J.L., Galid A., Wheeler T., Pujol B., Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy—data from the CHOICE study, Curr Med Res Opin, 27, 5, pp. 987-994, (2011)

← 1 2 →